Total lymphoid irradiation in heart transplantation

Long-term efficacy and survival-an 18-year experience

José A. Tallaj, Salpy V. Pamboukian, James F. George, Robert N. Brown, Octavio E. Pajaro, Robert C. Bourge, Martin Cadeiras, Melissa Smallfield, James K. Kirklin, David C. McGiffin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. Total lymphoid irradiation (TLI) has been used in transplantation for over 20 years and is currently used in a number of major heart transplant centers as a secondary therapy for recalcitrant recurrent rejection or rejection with hemodynamic compromise. The purpose of this study is to evaluate the long-term risks and efficacy of TLI in the treatment of rejection. Methods. Between 1990 and 1996, 73 adult patients (from 211 adult transplant recipients) received TLI for recurrent rejection (71%), rejection with hemodynamic compromise (25%), and rejection with vasculitis (4%). The treatment consisted of 80 cGy twice per week for 5 weeks. Fifty-five patients received at least 80% of the full dose (>640 cGy). Follow-up ended December 31, 2007, comprising a total 18 year experience. Results. Patients treated with TLI exhibited a short-term decrease in hazard for rejection in the first 12 months posttransplantation (relative risk, 0.36) but exhibited increased cumulative rejection over the long term. There were no differences in the rates of infection, allograft coronary disease, or malignancy, but seven patients developed myelodysplasia or acute myelogenous leukemia, four of those being the rare but uniformly fatal acute megakaryocytic leukemia type 7. Conclusions. Patients treated with TLI seemed to experience a reduction in the early hazard for rejection, but long-term outcomes indicate that such patients continued to accumulate more rejection and rejection-death events, likely because these patients were overall at much higher risk for rejection than the other patient groups. We observed minimal long-term complications, except for the unique occurrence of myelodysplasia and acute megakaryocytic leukemia type 7.

Original languageEnglish (US)
Pages (from-to)1159-1164
Number of pages6
JournalTransplantation
Volume92
Issue number10
DOIs
StatePublished - Nov 27 2011
Externally publishedYes

Fingerprint

Lymphatic Irradiation
Heart Transplantation
Survival
Leukemia, Megakaryoblastic, Acute
Hemodynamics
Vasculitis
Acute Myeloid Leukemia
Allografts
Coronary Disease
Therapeutics
Transplantation
Transplants

Keywords

  • Heart transplantation
  • Outcomes
  • Total lymphoid irradiation

ASJC Scopus subject areas

  • Transplantation

Cite this

Tallaj, J. A., Pamboukian, S. V., George, J. F., Brown, R. N., Pajaro, O. E., Bourge, R. C., ... McGiffin, D. C. (2011). Total lymphoid irradiation in heart transplantation: Long-term efficacy and survival-an 18-year experience. Transplantation, 92(10), 1159-1164. https://doi.org/10.1097/TP.0b013e318231e9d3

Total lymphoid irradiation in heart transplantation : Long-term efficacy and survival-an 18-year experience. / Tallaj, José A.; Pamboukian, Salpy V.; George, James F.; Brown, Robert N.; Pajaro, Octavio E.; Bourge, Robert C.; Cadeiras, Martin; Smallfield, Melissa; Kirklin, James K.; McGiffin, David C.

In: Transplantation, Vol. 92, No. 10, 27.11.2011, p. 1159-1164.

Research output: Contribution to journalArticle

Tallaj, JA, Pamboukian, SV, George, JF, Brown, RN, Pajaro, OE, Bourge, RC, Cadeiras, M, Smallfield, M, Kirklin, JK & McGiffin, DC 2011, 'Total lymphoid irradiation in heart transplantation: Long-term efficacy and survival-an 18-year experience', Transplantation, vol. 92, no. 10, pp. 1159-1164. https://doi.org/10.1097/TP.0b013e318231e9d3
Tallaj, José A. ; Pamboukian, Salpy V. ; George, James F. ; Brown, Robert N. ; Pajaro, Octavio E. ; Bourge, Robert C. ; Cadeiras, Martin ; Smallfield, Melissa ; Kirklin, James K. ; McGiffin, David C. / Total lymphoid irradiation in heart transplantation : Long-term efficacy and survival-an 18-year experience. In: Transplantation. 2011 ; Vol. 92, No. 10. pp. 1159-1164.
@article{eabce21175654290975a118e9d00d754,
title = "Total lymphoid irradiation in heart transplantation: Long-term efficacy and survival-an 18-year experience",
abstract = "Background. Total lymphoid irradiation (TLI) has been used in transplantation for over 20 years and is currently used in a number of major heart transplant centers as a secondary therapy for recalcitrant recurrent rejection or rejection with hemodynamic compromise. The purpose of this study is to evaluate the long-term risks and efficacy of TLI in the treatment of rejection. Methods. Between 1990 and 1996, 73 adult patients (from 211 adult transplant recipients) received TLI for recurrent rejection (71{\%}), rejection with hemodynamic compromise (25{\%}), and rejection with vasculitis (4{\%}). The treatment consisted of 80 cGy twice per week for 5 weeks. Fifty-five patients received at least 80{\%} of the full dose (>640 cGy). Follow-up ended December 31, 2007, comprising a total 18 year experience. Results. Patients treated with TLI exhibited a short-term decrease in hazard for rejection in the first 12 months posttransplantation (relative risk, 0.36) but exhibited increased cumulative rejection over the long term. There were no differences in the rates of infection, allograft coronary disease, or malignancy, but seven patients developed myelodysplasia or acute myelogenous leukemia, four of those being the rare but uniformly fatal acute megakaryocytic leukemia type 7. Conclusions. Patients treated with TLI seemed to experience a reduction in the early hazard for rejection, but long-term outcomes indicate that such patients continued to accumulate more rejection and rejection-death events, likely because these patients were overall at much higher risk for rejection than the other patient groups. We observed minimal long-term complications, except for the unique occurrence of myelodysplasia and acute megakaryocytic leukemia type 7.",
keywords = "Heart transplantation, Outcomes, Total lymphoid irradiation",
author = "Tallaj, {Jos{\'e} A.} and Pamboukian, {Salpy V.} and George, {James F.} and Brown, {Robert N.} and Pajaro, {Octavio E.} and Bourge, {Robert C.} and Martin Cadeiras and Melissa Smallfield and Kirklin, {James K.} and McGiffin, {David C.}",
year = "2011",
month = "11",
day = "27",
doi = "10.1097/TP.0b013e318231e9d3",
language = "English (US)",
volume = "92",
pages = "1159--1164",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Total lymphoid irradiation in heart transplantation

T2 - Long-term efficacy and survival-an 18-year experience

AU - Tallaj, José A.

AU - Pamboukian, Salpy V.

AU - George, James F.

AU - Brown, Robert N.

AU - Pajaro, Octavio E.

AU - Bourge, Robert C.

AU - Cadeiras, Martin

AU - Smallfield, Melissa

AU - Kirklin, James K.

AU - McGiffin, David C.

PY - 2011/11/27

Y1 - 2011/11/27

N2 - Background. Total lymphoid irradiation (TLI) has been used in transplantation for over 20 years and is currently used in a number of major heart transplant centers as a secondary therapy for recalcitrant recurrent rejection or rejection with hemodynamic compromise. The purpose of this study is to evaluate the long-term risks and efficacy of TLI in the treatment of rejection. Methods. Between 1990 and 1996, 73 adult patients (from 211 adult transplant recipients) received TLI for recurrent rejection (71%), rejection with hemodynamic compromise (25%), and rejection with vasculitis (4%). The treatment consisted of 80 cGy twice per week for 5 weeks. Fifty-five patients received at least 80% of the full dose (>640 cGy). Follow-up ended December 31, 2007, comprising a total 18 year experience. Results. Patients treated with TLI exhibited a short-term decrease in hazard for rejection in the first 12 months posttransplantation (relative risk, 0.36) but exhibited increased cumulative rejection over the long term. There were no differences in the rates of infection, allograft coronary disease, or malignancy, but seven patients developed myelodysplasia or acute myelogenous leukemia, four of those being the rare but uniformly fatal acute megakaryocytic leukemia type 7. Conclusions. Patients treated with TLI seemed to experience a reduction in the early hazard for rejection, but long-term outcomes indicate that such patients continued to accumulate more rejection and rejection-death events, likely because these patients were overall at much higher risk for rejection than the other patient groups. We observed minimal long-term complications, except for the unique occurrence of myelodysplasia and acute megakaryocytic leukemia type 7.

AB - Background. Total lymphoid irradiation (TLI) has been used in transplantation for over 20 years and is currently used in a number of major heart transplant centers as a secondary therapy for recalcitrant recurrent rejection or rejection with hemodynamic compromise. The purpose of this study is to evaluate the long-term risks and efficacy of TLI in the treatment of rejection. Methods. Between 1990 and 1996, 73 adult patients (from 211 adult transplant recipients) received TLI for recurrent rejection (71%), rejection with hemodynamic compromise (25%), and rejection with vasculitis (4%). The treatment consisted of 80 cGy twice per week for 5 weeks. Fifty-five patients received at least 80% of the full dose (>640 cGy). Follow-up ended December 31, 2007, comprising a total 18 year experience. Results. Patients treated with TLI exhibited a short-term decrease in hazard for rejection in the first 12 months posttransplantation (relative risk, 0.36) but exhibited increased cumulative rejection over the long term. There were no differences in the rates of infection, allograft coronary disease, or malignancy, but seven patients developed myelodysplasia or acute myelogenous leukemia, four of those being the rare but uniformly fatal acute megakaryocytic leukemia type 7. Conclusions. Patients treated with TLI seemed to experience a reduction in the early hazard for rejection, but long-term outcomes indicate that such patients continued to accumulate more rejection and rejection-death events, likely because these patients were overall at much higher risk for rejection than the other patient groups. We observed minimal long-term complications, except for the unique occurrence of myelodysplasia and acute megakaryocytic leukemia type 7.

KW - Heart transplantation

KW - Outcomes

KW - Total lymphoid irradiation

UR - http://www.scopus.com/inward/record.url?scp=80855131621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855131621&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e318231e9d3

DO - 10.1097/TP.0b013e318231e9d3

M3 - Article

VL - 92

SP - 1159

EP - 1164

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -